European Psychiatry - Volume 33 - March 2016

98 / 812

S94 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S72–S115
FC53
Co-occurrence of PTSD and
cardiovascular disease among
ethnic/racial groups in the United
States
C. Vidal Mari˜no ∗, R. Polo del Rio , M. Alegría , Y. Wang ,
R. Carmona
1 Fundación Jiménez Díaz, Departamento de Psiquiatría, Madrid,
Spain
2 Massachusetts General Hospital, Disparities Research Unit, Boston,
USA
∗ Corresponding author.
Introduction Some inconsistent evidence indicates experiences
of trauma and the presence of symptoms of PTSD are associated
with increased risk of cardiovascular diseases. This relation has
rarely been explored with community samples including partici-
pantswith PTSD symptoms orwho fulfill criteria for PTSDdisorders.
Objectives We identify those with a high number of PTSD symp-
toms and those fulfilling criteria for PTSD are more likely to have
CVD than thosewithout a PTSD syndrome or examine
rates of mental health access for those with PTSD and CVD.
Methods We use Collaborative Psychiatric Epidemiology Surveys
(CPES) to examine differences in trauma/PTSD prevalence and the
association of prior trauma exposure and PTSD diagnoses with CVD
(n = 13,286). CIDI was used tomake psychiatric diagnoses andmed-
ical data was acquired regarding onset and severity of CVD.
Results Individuals with prior exposure to trauma and PTSD diag-
noses had twice the likelihood of developing a cardiovascular
disease as those without trauma exposure [OR = 1.77, 95% CI (1.0,
2.94)]. Having a PTSD diagnosis is a significant predictor of having
a CVD for individuals who experienced a traumatic event.
The probability of developing a CVD was higher when patients had
prior diagnosis of substance abuse [OR = 1.36, 95% CI (1.11, 1.65)] or
mental health disorders [OR = 1.43, 95% CI (1.10, 1.87) for depres-
sion; OR = 1.33, 95% CI (1.04, 1.69) for anxiety]. Men were almost
twice as likely as women to be diagnosed with a CVD [OR = 1.67,
95% CI (1.37, 2.00)].
Conclusions Exposure to trauma and the presence of PTSD symp-
toms are significantly associated with CVD.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
Prevention of mental disorders
FC54
Prevalence of the metabolic syndrome
in patients at risk of psychosis
J. Cordes ∗, A. Bechdolf , S. Moebus
1 Medical Faculty, Düsseldorf, Germany
2 Klinik für Psychiatrie-Psychotherapie und Psychosomatik, Vivantes
Klinikum am Urban, Akademisches Lehrkrankenhaus, Berlin,
Germany
3 Zentrum Urbane Epidemiologie Cue, Universitätsklinikum Essen,
Universität Duisburg-Essen, Essen, Germany
∗ Corresponding author.
Themetabolic syndrome (MetS) is one of themost frequent reasons
for the higher mortality in patients with schizophrenia. It is difficult
to separate between effects of medication or the disorder itself on
the development of MetS. In the present study, patients at clinical
high risk for first-episode psychosis (CHR) were examined and the
prevalence of the MetS was assessed. One hundred and sixty-three
unmedicated antipsychotic naïve CHR patients aged between 18
and 42 years and suffering from unmanifested prodromal symp-
toms were compared to 35,869 patients of the “German Metabolic
and Cardiovascular Risk Study” (GEMCAS). We observed a slightly
higher prevalence of single MetS criteria in CHR group compared
to the GEMCAS sample, in particular: high blood pressure (35.0
vs. 28.0%), waist circumference (17.6 vs. 15.1%), and high fasting
blood glucose (9.4 vs. 4.0%). We assume the higher risk for MetS
in schizophrenia patients or CHR patients to derive from genetic
factors.
Disclosure of interest In cooperation with Joachim Cordes,
Andreas Bechdolf, Christina Engelke, Kahl KG, Chakrapani Bali-
jepalli, Christian Lösch, Joachim Klosterkötter, Michael Wagner,
Wolfgang Maier, Andreas Heinz, Walter de Millas, Wolfgang
Gaebel, Frank Schneider, Martin Lambert, Georg Juckel, Thomas
Wobrock, Michael Riedel, Susanne Moebus.
Psychoneuroimmunology
FC55
Inflammatory cytokines and
glutaminergic excitotoxicity in
patients with obsessive-compulsive
disorder (OCD)
S. Gnanavel ∗, A. Parmar , P. Sharan , V. Subbiah , U. Sharma ,
N.R. Jagannathan
1 St Mary’s Hospital, CAMHS, Department of Psychiatry, Kettering,
United Kingdom
2 All India Institute of Medical Sciences, Psychiatry, New Delhi, India
3 All India Institute of Medical Sciences, Neurobiochemistry, New
Delhi, India
4 All India Institute of Medical Sciences, NMR and MRI Facility, New
Delhi, India
∗ Corresponding author.
Introduction In vitro studies have demonstrated possible neu-
roprotective effects of the following pro-inflammatory cytokines:
IL-6, IL-1 and TNF- against glutaminergic excitotoxicity in brain
through different pathways.
Objectives In the current study, we aim to correlate level of the
above pro-inflammatory cytokines in serum with glutamate lev-
els in head of caudate nucleus measured using Proton Magnetic
Resonance Spectroscopy (1H-MRS) in patients with obsessive-
compulsive disorder (OCD), a neuropsychiatric illnesswith possible
multifactorial aetiology including immunological and excitotoxic
factors.
Method Thirty psychotropic-naïve patients with OCD and an
equal number of gender and age-matched normal controls were
recruited in the study. A detailed psychiatric assessment was car-
ried out including sociodemographic and clinical variables. A 3T
MR imaging and spectroscopy session was carried out in head
of caudate nucleus. Further, absolute quantification of glutamate
level was obtained using LC model. Simultaneously, 5mL of blood
sample was collected and assayed for the above pro-inflammatory
cytokines (Siemens, ImmuliteTM). The level of glutamate was cor-
related with the cytokine levels in patients with OCD.
Results The level of Glx was significantly higher in patients with
OCD as compared to controls (P < 0.05). The Glx level negatively
correlated with two of the three pro-inflammatory cytokines: IL-
6 and TNF- (r = −0.807; r= −0.838; P < 0.05) while no significant
correlation was demonstrated with IL-1 .
Conclusions The findings provide preliminary evidence regarding
possible neuroprotective effects of pro-inflammatory cytokines